Phenotypic studies with carefully selected biomarkers like CD5 and FOXP1 are able to prognosticate DLBCL course at diagnosis, independent of stage and IPI and independent of response to R-CHOP. The gene discussed is FOXP1; the disease is diffuse large B-cell lymphoma.